Rohto Pharmaceutical

Basic Information

Stock Code: 4527
Industry: Pharmaceuticals
Category Detail: Biotechnology & Pharmaceuticals
Prefecture: Osaka Prefecture
Establishment Year: September 1949
Listing Year: October 1961
Official Website: https://www.rohto.co.jp/
TSE Information: TSE Information
Yahoo! Finance: Yahoo! Finance
Other Companies: Tsumura, Daikokuyakuhin, Otsuka HD, Lion

Overview

Rohto Pharmaceutical is a pharmaceutical manufacturer established in 1949, holding top-class market share in Japan in over-the-counter drugs, health foods, and cosmetics.

Current Situation

Rohto Pharmaceutical achieved consolidated sales of 270.8 billion yen and operating profit of 40 billion yen in the fiscal year ending March 2024, maintaining a solid financial base. In the over-the-counter drug market, it boasts high market share in eye drops and gastrointestinal drugs, particularly maintaining the top domestic share in eye drops. Through group companies, it also develops prescription pharmaceuticals, enhancing expertise in ophthalmology, otolaryngology, and proctology. It is expanding into functional cosmetics and health foods, actively developing new brands and pursuing technological innovation. It is proactively addressing environmental, social, and governance (ESG) issues, focusing on regional contributions and disaster support. In the medium to long term, it aims for sustainable growth by strengthening business expansion domestically and internationally and enhancing competitiveness through digital technology adoption.

Trivia

Interesting Facts

Rohto Eyedrops, launched in 1909, became a hit product due to the invention of the dual-nozzle eyedrop bottle.
The flagship eye drop brand 'V・Rohto' has been offered since 1964 as a traditional product.
Acquired domestic manufacturing and sales rights for Mentholatum in 1975, advancing diversification.
Head office located in Ikuno-ku, Osaka City, representing Osaka's pharmaceutical industry.
Started with sales of gastrointestinal drugs, and Pansiron is a long-life brand.
Maintains top domestic share in eye drops.
Corporate slogan refreshed to 'Rohto is Heart.' to strengthen brand value.
Conducts cutting-edge research with labs and offices in Grand Front Osaka.
Has featured many celebrities in TV commercials, boasting high recognition.
Actively advancing into functional foods, health foods, and cosmetics.

Hidden Connections

Founder Yasutami Yamada is related by blood to Tsumura founder, with mutual support in early days.
Acquisition of Mentholatum gave influence in North American market, accelerating global expansion.
Lab in Grand Front Osaka's Kita-ku is in same area as Santen Pharmaceutical, contributing to industry hub formation.
Sponsor of Chiba Lotte Marines, focusing on sports marketing.
Mutual interest with Yakult Honsha and Otsuka Holdings in health food sector.
Built trust from long-term investors through continuous dividend increases.
Operates unique scent design lab, applying olfactory science to product development.
Pioneering CSR activities in Japan's social and health fields, building new regional collaboration model.

Future Outlook

Growth Drivers

New product development in functional cosmetics and health foods
Introduction of digital health technologies and manufacturing innovation using IoT
Expansion of OTC drug markets domestically and internationally
Active investment and technological innovation in regenerative medicine
Strengthening of eco-friendly products and sustainable brands
Expansion of pet health food business
Growth potential in sports-related products
Enhanced brand deployment in global markets
Trust building through strengthened regional collaborations
Increased market entry opportunities through regulatory adaptation
Differentiated product creation via R&D investment
Product development aimed at healthy longevity and QOL improvement

Strategic Goals

Maintain and expand share in domestic eye drop market
Expand sales of functional health foods and cosmetics to over 30% of total
Achieve revenue generation in regenerative medicine and gain technology leadership
Raise overseas sales ratio to over 25%
Achieve CO2 reduction targets and promote environmental load reduction
Establish diversity respect and supportive corporate culture
Create new businesses through open innovation
Establish high-functionality cosmetics brands domestically and internationally
Improve customer experience through digitalization
Elevate regional social contribution activities to sustainable business

Business Segments

Prescription Pharmaceuticals Business

Overview

Researches, manufactures, and sells specialized pharmaceuticals for ophthalmology, otolaryngology, and proctology. Provided through group companies.

Competitiveness

Specialized product lineup and high technological capabilities

Customers

Ophthalmology Clinics
Otolaryngology Clinics
Specialty Hospitals

Products

Ophthalmic Eye Drops
Otolaryngology Pharmaceuticals
Proctology Pharmaceuticals

R&D and Contract Manufacturing

Overview

Offers contract manufacturing for pharmaceuticals and health-related products, as well as R&D support services.

Competitiveness

Advanced facilities and extensive development expertise

Customers

Pharmaceutical Companies
Biotech Companies
Cosmetics Manufacturers

Products

Pharmaceutical Contract Manufacturing
Functional Cosmetics Development Support
Health Food OEM

Health-Related Services and Products

Overview

B2B sales of health foods and sports-related products, along with service provision.

Competitiveness

Diverse product lineup and industry network

Customers

Retailers
Mail-Order Businesses
Sports Facilities

Products

Health Supplements
Sports Nutrition Products
Health Promotion Programs

Pet Health Supplements

Overview

New business field handling planning, manufacturing, and sales of health foods for pets.

Competitiveness

Market development of dog supplement 'Rohto V5 Wan'

Customers

Pet Shops
Veterinary Clinics
Pet Supply Stores

Products

Dog Health Supplements
Pet Nutritional Supplements

Competitive Advantage

Strengths

Top domestic market share in eye drops
Diversified health-related product portfolio
Long history and trusted brand power
Prescription pharmaceuticals expansion via group companies
Advanced R&D capabilities
Stable financial base
Effective marketing strategies
Nationwide distribution network
Advanced manufacturing technology
Diverse sales channels

Competitive Advantages

Efficient management by handling prescription drugs through specialized subsidiaries rather than direct entry
Competitive edge from technological innovations such as inventing the dual-nozzle eyedrop bottle
Established brands with strengths in pillar products like eye drops and gastrointestinal drugs
New growth drivers from expansion into functional cosmetics and health foods
Active CSR activities in regional society and environment contributing to brand value enhancement
Investor support gained from stable dividend policy
High credibility and recognition since listing
Broad customer needs coverage with diverse product range
Continuous investment in R&D and new technology adoption
Global market対応 via overseas subsidiaries

Threats

Maturing and shrinking domestic pharmaceutical market
Intensified competition from rivals' new products and price wars
Market share pressure from new entrants
Increased business costs from regulatory changes
Risks of rising raw material and logistics costs
Shifts in product demand due to changing consumer health awareness
Impact of exchange rate fluctuations on earnings
Supply chain risks from natural disasters, etc.
Impact on overseas operations from unstable international situation
Information security risks

Innovations

2024: New CI Logo and Corporate Slogan Refresh

Overview: Refreshed logo and slogan on the occasion of 125th anniversary to reinforce brand image.
Impact: Improved customer recognition and brand value

2024: Full Entry into Hair Care Market

Overview: Launched new products in hair care with 'Proly' and 'Gyutto' brands.
Impact: Acquisition of new customer segments and sales expansion

2023: New Brand Development for Health Foods x Beverages

Overview: Jointly launched functional beverage 'Senovik Milk Cocoa Flavor' with Sujata Meiraku Group.
Impact: Market share expansion in health food sector

2022: Free Release of Monitoring System

Overview: Developed and released IoT system to detect anomalies in manufacturing equipment, improving production efficiency.
Impact: Enhanced maintenance of production lines and cost reduction

2021: Subsidiary Acquisition in Regenerative Medicine

Overview: Made Olympus RMS Co., Ltd. a subsidiary to advance R&D in cartilage transplantation technology, etc.
Impact: Business expansion and technology acquisition in regenerative medicine

2020: Subsidiary Acquisition for Ophthalmic Prescription Eye Drops

Overview: Acquired all shares of Japan Ophthalmic Laboratory to strengthen development of ophthalmic prescription drugs.
Impact: Enhanced competitiveness in ophthalmology

2020: Launch of New Skin Care Brand 'SKIO'

Overview: Launched Z-generation targeted skin care brand via D2C model on EC site.
Impact: Strengthened appeal to youth and new customer acquisition

2020: Eye Drop Renewal and Eco Packaging Introduction

Overview: Improved formulations of major eye drop series and switched to eco packaging with reduced package inserts.
Impact: Reduced environmental impact and improved product satisfaction

2023: Launch of Functional Cosmetics 'Derma Sept RX' Series

Overview: Launched functional cosmetics with usage guidance at medical institutions, available via mail order only.
Impact: Entry into high-value-added market

2023: Launch of Environmentally Friendly Skin Care Brand 'Calamee'

Overview: Announced new skin care brand addressing Z-generation skin concerns with eco-friendly ingredients.
Impact: Acquisition of sustainability-oriented customers

Sustainability

Promotion of CO2 emission reduction projects in manufacturing processes
Reduction of plastic in product packaging and promotion of reuse
Health awareness activities for local communities
Ongoing disaster recovery support activities
Strengthened environmental and human rights considerations in supply chain
Increased utilization ratio of renewable energy
Enhanced regional collaboration through CSR activities
Efforts toward sustainable product development
Promotion of diversity and work-life balance for employees
Creation of safe and reassuring workplace environment